In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Lessons Learned After 500 Cases of Intra-Arterial Chemotherapy for Retinoblastoma

    Final Number:
    118

    Authors:
    Elias Atallah MD; Stavropoula I. Tjoumakaris MD; Robert H. Rosenwasser MD, FACS, FAHA; Pascal Jabbour MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Intra-arterial chemotherapy has been used in early-childhood retinoblastoma. We present some pearls and pitfalls of this technique in a sizable cohort of retinoblastoma patients.

    Methods: A retrospective, non-comparative cohort of 500 patients with retinoblastoma was grouped between January 2009 and September 2016. Melphalan was infused under fluoroscopic guidance through the ophthalmic artery with supplementary topotecan or carboplatin or both, for a mean of 3 cycles. The mean follow-up was 20.3 months(SD=11.3). The International Classification of Retinoblastoma(ICRB) was implemented in the assessment of ocular globe preservation and of the tumor’s response to treatment. Grade E patients were almost always treated concomitantly with IV chemotherapy.

    Results: Of 500 patients (mean of age 35 months), we treated 520 eyes. (n1= 236; [(67) A, (83) B, (48) C, (18) D and (20) E]) received a primary treatment, (n2= 95) were treated for their advanced disease, (n3= 67) had bilateral retinoblastoma and (n4= 55) were treated for a recurrence after conventional intravenous chemotherapy. Globe preservation was achieved in 87% of primary-treated cases(A [100%]; B [100%]; C [100%]; D [92%]; E [46%]) and in 69% of secondary-treated patients. Postprocedural complications were vitreous hemorrhage (3.2%), retinal artery branch occlusion (0.75%), ophthalmic artery (OA) occlusion (1.7%) and spasm (2.2%), limited choroidal ischemia (1.8%) and optic neuropathy (0.7%). 478(92%) patients had complete regression: small tumors 99%[201/203]; well-defined tumors 97%[173/178] and poorly defined tumors 92%[88/97]. There was no motor, sensitive or ictal complications after the intervention. Patients manifested none of the systemic side effects of the dispensed chemotherapy.

    Conclusions: Selective intra-ophtalmic chemotherapy has become a gold standard in the treatment of retinoblastoma, with very low mortality, morbidity related to the procedure and a very high cure rate.

    Patient Care: This technique would reduce the risk of enucleation and for it holds a minimal risk of local and systemic complications. All neurointerventionists will be able to perform this technique with remarkable success rates.

    Learning Objectives: intra-ophtalmic chemotherapy for retinoblastoma is safe and efficacious with a very low risk of morbi-mortality.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy